Innovation matters most when patients can reach it

A Moment for Optimism

When a family member is diagnosed with cancer or a rare disease, the diagnosis never belongs to one person alone. It reaches an entire family, and often a wider community. In those moments, innovation stops being an abstract idea discussed in laboratories, boardrooms, or policy forums. It becomes hope, time, and the possibility of a better outcome.

As the UAE marks the Year of Family 2026, this message carries added meaning. Access to healthcare innovation is not only about better outcomes for individual patients; sustained, long-term access to care also helps strengthen the resilience of families facing health challenges and the wider social cohesion that comes from communities standing behind them.

This is the spirit behind the new collaboration between The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) and the Authority of Social Contribution – Ma’an.

Who Is Involved, and Why It Matters

PHRMAG represents leading innovative biopharmaceutical research companies operating across the Gulf region, whose member companies are committed to developing medicines that help patients live longer, healthier lives, while supporting responsible dialogue and better patient outcomes across the region's health systems.

The Authority of Social Contribution - Ma’an is Abu Dhabi Government’s official channel to receive social contributions, dedicated to uniting community efforts and directing contributions towards social priorities across multiple sectors in Abu Dhabi, including healthcare.

Through this collaboration, PHRMAG and the Authority aim to support eligible oncology and rare disease patients' access to innovative treatments within a structured framework aligned with the national health insurance system.

The partnership was witnessed and welcomed by the Department of Health – Abu Dhabi, which highlighted its contribution to accessible healthcare, innovation and research, and the early detection and treatment of rare diseases.

Access Is the Next Frontier

Medical innovation is moving at extraordinary speed. New therapies, earlier diagnosis, and more personalized care are changing what is possible for patients, including those living with diseases that once had limited treatment options.

Access is what enables innovation to move from scientific progress to meaningful, real-world impact. This is especially important in areas such as rare diseases, where individual patient populations may be small, but the need for timely diagnosis, specialized care, and treatment options can be significant. According to the World Health Organization, more than 300 million people worldwide live with one of more than 7,000 rare diseases.

The scale of need in oncology is also clear. According to the International Agency for Research on Cancer, the World Health Organization’s cancer agency, there were an estimated 20 million new cancer cases and 9.7 million cancer deaths globally in 2022.

For me, this is both the promise and the responsibility of innovation. A treatment may exist, a system may be advanced, and a pathway may be clinically sound. But progress becomes real only when the patient who needs that treatment can access it at the right time.

That is the gap this partnership is designed to help close.